Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

127.99 +0.49 (+0.38%)
Official Closing Price Updated: 7:00 PM EDT, Jun 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
67 68 Next >
Dividend Stocks Alert: 10 Top Holdings From the SCHD ETF
Dividend funds like the SCHD ETF are gaining traction ahead of its March 27 dividend payment. What are the top 10 holdings in the ETF? 
Via InvestorPlace
OPKO Health's Cancer & Infectious Disease Focused Subsidiary Inks Vaccine Development Pact With Merck
Via Benzinga
2 Top Healthcare Stocks to Buy Right Now
Most people eventually need the healthcare goods/services that these companies provide. 
Via The Motley Fool
Beat the Dow Jones With This Unstoppable Dividend Stock
Merck had a strong year and has the portfolio and pipeline to increase its dividend. 
Via The Motley Fool
Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason
Via Benzinga
Merck Highlights Promising Data From Two Candidates In Heart Diseases
Via Benzinga
Merck Discontinues Two Keytruda Combo Therapy Trials In Prostate & Lung Cancer Settings
Via Benzinga
Here's How Much $1000 Invested In Merck & Co 5 Years Ago Would Be Worth Today
Via Benzinga
Analyst Downgrades Gossamer Bio As Merck's Sotatercept Might Overshadow Seralutinib's Success
Via Benzinga
Keytruda Who? Merck Nears Breakout On $10 Billion Sales Potential For Heart Drugs
The heart segment is becoming more important as Keytruda near patent expiration. 
Via Investor's Business Daily
DocuSign To Rally Around 25%? Here Are 10 Other Analyst Forecasts For Tuesday
Wells Fargo cut the price target for Cheniere Energy, Inc. (NYSE: LNG) from $236 to $230. Wells Fargo analyst Michael Blum maintained an Overweight rating. Cheniere Energy shares fell 4.8% to close at... 
Via Benzinga
Healthcare Is Lagging But Biotech Offers Good Potential For Value And Trading
Over the past week, the market had a nice uptick making it harder for defensive sectors like healthcare to get traction up only 0.51% and down almost 5% YTD. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For March 6, 2023
Via Benzinga
US Senators Warren, Sanders Urge 'Close Scrutiny' On Merck's Keytruda-Related Patents
Via Benzinga
Secrets Of Great Long-Term Stock Investors
What can the rest of us learn from Warren Buffett's long-term stock buys? Here are 5 stock ideas for long-term investors. 
Via Talk Markets
Week In Review: Abbisko Out-Licenses Rights To Precision NSCLC Medicine For $188 Million
Abbisko Therapeutics out-licensed Greater China rights to a pre-clinical EGFR-TKI candidate for NSCLC to Allist Pharma in a $188 million deal. Also, Chipscreen Bio acquired greater China rights to a... 
Via Talk Markets
After Shelving Two Keytruda Trials, Merck Touts Encouraging Data From Keytuda Regime Study In Lung Cancer Patients
Via Benzinga
Why Compugen Shares Are Up Today
The company released its fourth-quarter and full-year results after the bell Monday. 
Via The Motley Fool
Analyst Cautions Investors On Overreacting To 'Early-Stage' Pfizer/Seagen Discussions
Via Benzinga
'Here We Go Again': Seagen Soars As Pfizer Reportedly Mulls A Takeover
The potential deal follows rumors last year that Merck could buy Seagen. 
Via Investor's Business Daily
European Authority Recommends Against Approval For Merck-Ridgeback Biotherapeutics' COVID-19 Pill
Via Benzinga
Expert Ratings for Merck & Co
Via Benzinga
Seagen Stock Soars On Pfizer Takeover Talks: What's Going On?
Seagen Inc (NASDAQ: SGEN) shares are trading higher Monday following reports indicating pharmaceutical giant Pfizer Inc (NYSE: 
Via Benzinga
Pfizer In Early Talks To Buy Cancer-Focused Seagen: WSJ
Via Benzinga
Buy/Sell: Wall Street's Top 10 Stock Calls This Week - Saturday, Feb. 25
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street’s best analysts during the week of Feb. 20-24. 
Via Talk Markets
The Next Generation Of Cancer Vaccines Are Coming; What That Means For Moderna And Other Biotech Stocks
Startling cancer vaccine results from Moderna may point to the next big thing in biotech. 
Via Investor's Business Daily
Don't Get Panicked Into Selling Off Merck Shares
The current drop in 2023 sales likely won't matter in the long term. 
Via The Motley Fool
Infinity Pharmaceuticals Announce Merger Agreement With MEI Pharma, Share Plunge
Via Benzinga
Moderna Pops After FDA Grants Its Cancer Vaccine A Breakthrough Designation
The companies could see a speedier review process. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For February 22, 2023
Via Benzinga
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
67 68 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.